来源：药渡撰文：Pharmadeep编辑：维他命7月29日，跨国药企巨头阿斯利康（AstraZeneca）发布2025年上半年财报，交出一份超预期的成绩单：总营收达280.45亿美元（按固定汇率CER计算），同比增长11%；研发投入67.07亿美元，同比激增16%。这份财报不仅展现了其核心业务的强劲增长，更揭示了其在ADC、双抗等前沿领域的战略野心——肿瘤板块以119.54亿美元（增长16%）贡献...
Source Link来源：药渡撰文：Pharmadeep编辑：维他命7月29日，跨国药企巨头阿斯利康（AstraZeneca）发布2025年上半年财报，交出一份超预期的成绩单：总营收达280.45亿美元（按固定汇率CER计算），同比增长11%；研发投入67.07亿美元，同比激增16%。这份财报不仅展现了其核心业务的强劲增长，更揭示了其在ADC、双抗等前沿领域的战略野心——肿瘤板块以119.54亿美元（增长16%）贡献...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.